CORXEL’s Dr. Bo Liang on why small molecule oral therapies will be the long-term winners in a GLP-1 market driven by consumer preference.
|Articles|May 1, 2008
- Pharmaceutical Executive-05-01-2008
- Volume 0
- Issue 0
Pharm Exec 50: The Winners’ Circle
Your guide to the world's top 50 pharma companies. The giants may be struggling, but even in a tough year, the industry's most successful companies know how to hit the bullseye.
Advertisement
Articles in this issue
over 18 years ago
How Not to Handle Rebatesover 18 years ago
Want to Be in a Health Plan? Think Like Oneover 18 years ago
Special Report: Platform Drugs—Marketing Your Opportunitiesover 18 years ago
Q&A with Barbara Yanniover 18 years ago
Ready, Aim, Sellover 18 years ago
Staying in the Gameover 18 years ago
For the People, By the Peopleover 18 years ago
Under Pressureover 18 years ago
Korea's Dream Marketover 18 years ago
Special Report: Platform Drugs—Opportunities in the Market...Advertisement
Related to this article
Digital health's point-solution era is giving way to broader platforms, and the cost-savings claims those platforms make to employers often don't hold up to methodological scrutiny.
CORXEL’s Dr. Bo Liang on why efficacy is no longer obesity medicine's biggest gap — and the four unmet needs that define what comes next.
Dr. Jeremy Levin joins Ken Banta to share why he believes biotech's future demands a new level of leadership and stakeholder education — and why "mission without method" is a wasted effort.
Numerof's Michael Abrams on why directing employees to the most effective, economical clinicians is digital health's most valuable offering.
Numerof's Michael Abrams on why digital health's cost-savings claims often don't hold up to scrutiny — and why the evidence gap matters.
Numerof's Michael Abrams on why digital health's point-solution era is ending — and why consolidation into broader platforms is the next step.
Six years after Rutledge, new court rulings, federal PBM reforms, and state ownership bans are redrawing the limits of pharmacy benefit regulation.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: Novartis & Abogen Enter Licensing and Option Agreement, AstraZeneca and Daiichi Sankyo Enter Clinical Collaboration with Summit Therapeutics
2
Pharmaceutical Executive Daily: Foghorn Therapeutics & Eli Lilly Discontinue Development of FHD-909
3
Foghorn Therapeutics & Eli Lilly Halt Fhd-909 Development Following Phase I Data
4
New U.S. Guidance Lays Out Exemptions for 100% Tariffs: Report
5